Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Oncoheroes gains worldwide license to BI's shelved volasertib cancer compound

Executive Summary

Boehringer Ingelheim International GmbH licensed Oncoheroes Biosciences Inc. exclusive worldwide R&D and commercialization rights (and related IP) to its volasertib (BI6727), a polo-like-kinase 1 (PLK1) inhibitor for cancer.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Reverse Licensing
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register